I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Our 6 ‘Best Buys Now’ Shares Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge! Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before! The high-calibre small-cap stock flying under the City’s radar This could be one of the best shares to buy now for the post-lockdown world Kevin Godbold | Wednesday, 10th March, 2021 | More on: TTG Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. See all posts by Kevin Godbold Prior to the arrival of the pandemic, TT Electronics (LSE: TTG) appeared to be in a positive trend with earnings, cash flow and shareholder dividends rising each year.Why I think this is one of the best shares to buy nowThe company earns its living as a global provider of engineered electronics for performance-critical applications. And the directors reckon the business benefits from “enduring megatrends” in high-growth markets such as healthcare, aerospace, defence, electrification and automation.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…From day to day, TT Electronics designs and makes things such as sensors, connectors, hybrid microcircuits, power modules and sensors. And it does so from its facilities in the UK, North America, Sweden and Asia. On paper, the business is just the sort of thing I like to invest in. The set-up seems relevant in today’s world and it’s easy for me to imagine the enterprise growing over time as I hold the shares.Another thing I like is the small market capitalisation near £375m. The company resides in the FTSE Small Cap index, suggesting there’s plenty of room for the business to grow. However, a glance at the 20-year share price chart shows me the stock has essentially moved sideways this century. TT Electronics may be a small-cap, but it’s been little for a long time. And the undulating chart is a testament to the long-term volatility in the record of earnings.Right now, the company looks and sounds like a business recovering from the pandemic with tempting growth prospects ahead. But I suspect there’s a lot of cyclicality in the enterprise that could go on to unhinge a long-term investment in the stock. Nevertheless, I remain interested and consider it to be worth my further research time.A positive outlookToday’s full-year results report shows the damage caused by Covid. Constant currency revenue slipped by 9% in 2020 compared to the prior year and adjusted earnings per share plunged by 34%. But the directors reckon recovery is “well underway” and there was an increasing intake of orders and improved production capacity in the fourth quarter. Free cash flow was “strong” through the period and the directors have restored the shareholder dividend, “reflecting good recovery and a positive outlook.” Looking ahead, chief executive Richard Tyson reckons the positive structural trends in the company’s markets will likely accelerate. He thinks the longer-term effects of the pandemic could cause that situation. So the directors’ outlook statement is positive in both the short and long terms.But there’s still much that could go wrong for new shareholders from today. One risk is that a downturn in the industry could pull the rug from anticipated earnings. City analysts expect a robust double-digit rebound in earnings during 2021. But progress beyond the current year is uncertain.Meanwhile, the stock isn’t particularly cheap. The forward-looking earnings multiple for the current year is running just above 14. And the anticipated dividend yield is around 2.9%. I’m late to the opportunity. It would have been better to have bought some of the shares just under a year ago when they crashed. Nevertheless, I’m tempted to pick up a few now to hold for the long haul while being mindful of the risks in the post-lockdown world. Image source: Getty Images Enter Your Email Address Simply click below to discover how you can take advantage of this. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee.
May 7, 2021
Home » News » Housing Market » Leading property firm claims fall through rate of just 5% previous nextHousing MarketLeading property firm claims fall through rate of just 5%Buying agency Garrington says its model delivers lower sales fall-throughs as government grapples with its preferred solution – reservation agreements.Nigel Lewis3rd March 20201 Comment1,042 Views A buying agent has claimed that its sales fall-throughs rate for agreed purchases has bottomed out at 5% compared to a national average of between 25% and 30%.The claim has been made by Garrington, the buying agency originally set up by TV presenter Phil Spencer but now owned by its management.Garrington says it normally sees a fall-through rate of between 10% and 15% but, during one recent 12-month period, it reduced to five percent.The firm says its success is clear evidence that having a separate agent to represent the buyer and do much of the legwork helps prevent the majority of trip-ups that lead to deals falling through.Sales fall-throughs are on the political agenda. Matt Prior from the MHCLG gave a speech last week during which he said ministers were hoping to pilot an ‘industry standard’ reservation agreement later this year.And research by YouMoveNow recently revealed that the fall-through rate in some areas of the UK had reached 50% during the worst excesses of the ‘Brexit storm’ as buyer and seller jitters came to a crescendo.“Represented buyers are far less likely to withdraw from a transaction for a number of reasons,” says Garrington’s chief executive Jonathan Hopper (left).“They are likely to have been educated about market prices, better understand relative values and be much surer of what they really want from their next home having been challenged through the search process.“Critically, an experienced buying agent will have carried out extensive due diligence prior to agreeing terms for their client and entering into a transaction.“Finally, the positive working relationship that sales and buying agents enjoy in most instances allows for some fairly straight talking to take place during a transaction.“This allows for better management of expectations.”Matt Prior Garrington sales fall through MHCLG March 3, 2020Nigel LewisOne commentAndrew Stanton, CEO Proptech-PR Real Estate Influencer & Journalist CEO Proptech-PR Real Estate Influencer & Journalist 3rd March 2020 at 10:49 pmIf fall through rate is 5%, that is out of this world, the average fall through rate of all the agencies in the UK, in 2019, as a combined average rate was 22%. So over 1.6M properties listed between the agents, and from those which got to sold subject to contract, 22% fell through.At 5% that is a big achievement over 400% better than most agents. Might it be the number of Garrington transactions? In that if you did 100 sales, and 5 five fell through, that is your 5%. Obviously if you are doing volume like say Hunters who exchanged on over 11,000 last year, it would be hard to achieve a 5% fall through rate.Log in to ReplyWhat’s your opinion? Cancel replyYou must be logged in to post a comment.Please note: This is a site for professional discussion. Comments will carry your full name and company.This site uses Akismet to reduce spam. Learn how your comment data is processed.Related articles BREAKING: Evictions paperwork must now include ‘breathing space’ scheme details30th April 2021 City dwellers most satisfied with where they live30th April 2021 Hong Kong remains most expensive city to rent with London in 4th place30th April 2021
March 1, 2021
Robot builds erosion barriers from interlocking metal sheets, while robot swarms could protect threatened areas The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today the latest gift of $131 million from its founder, entrepreneur and philanthropist Hansjörg Wyss, M.B.A. ’65.The Wyss Institute seeks to bridge the gap between academia and industry by drawing inspiration from nature’s design principles to solve some of the world’s most complex challenges in health care and the environment and commercializing those solutions to maximize their impact.“Hansjörg Wyss has helped to expand what we know and what we can accomplish across a wide range of disciplines. The advances that his generosity has enabled will change the future for countless people,” said Harvard University President Larry Bacow. “His third gift to support the work of the Wyss Institute will ensure the continued success of our extraordinarily talented faculty and staff, as well as create new opportunities for collaboration and growth. We are deeply grateful for his support.”In 2009, Wyss made possible the Institute’s creation with a founding $125 million gift. A second gift to the University in 2013 enabled the Institute to grow and advance its pioneering work. The gift announced today will continue to enable the progress the Institute has made during its initial 10 years, amplify its already significant impact, and sustain its leadership in the field of biologically inspired engineering. Wyss’ giving over many years and across the University amounts to more than $400 million.“When talented, creative people are given the freedom to work together across disciplines, there are few problems they cannot solve,” said Wyss. “In the last decade, the Wyss Institute has made breakthrough after breakthrough to improve medicine and to apply the latest science to the betterment of peoples’ lives. I am happy to continue my support for the Wyss Institute and Harvard and look forward to seeing what the institute discovers and creates in the years ahead.”Wyss’ support for the Institute’s unique model — interdisciplinary collaboration among scientists and engineers from disparate fields along with expert staff with industrial experience — has led to sustained productivity in the past decade, including more than 2,600 patent filings, 53 licensing agreements, 29 startups, and numerous industry collaborations. The groundbreaking discoveries, designs, and technologies the institute has produced across a range of areas have a shared potential to improve human health and the environment on a global scale. Included among the breakthroughs Wyss’ gifts have enabled are:Cancer Vaccine,One of cancer’s most insidious tricks is deactivating the body’s immune cells, which normally find and kill malfunctioning cells. A project from the lab of core faculty member David Mooney, Robert B. Pinkas Family Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), in the Institute’s immuno-materials platform created a small implantable scaffold made of a biodegradable polymer that contains components derived from a patient’s cancer cells to act as “triggers.” When immune cells pass through the scaffold, they become activated and can successfully hunt and kill cancer cells elsewhere in the body. This process also creates a vaccine-like “memory” of the cancer so that any future cancer cells will also be killed. The technology was licensed by Novartis in 2018 and is currently in human clinical trials, where it is showing remarkable promise in treating patients with melanoma.Human Organs-on-Chips,Any drug that is developed for humans is first tested on animals to determine its safety and efficacy, but because animals are metabolically and genetically different from humans, drugs that work in mice or rats often fail in people. In addition, patients sometimes react differently to different drugs, but it is difficult to predict what those reactions will be before the drug is administered. One of the first startups founded to commercialize a Wyss technology, Emulate, Inc. aims to solve this problem with organs-on-chips: clear, flexible microfluidic chips that can be seeded with live human cells to recapitulate the function of human organs ex vivo. This technology was created in the Institute’s bioinspired therapeutics and diagnostics platform by the lab of Wyss Founding Director Donald Ingber, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and has the potential to eliminate animal testing, greatly accelerate the drug development process, and enable personalized medicine.Synthetic Biology-Enabled Molecular Diagnostics,Diagnosing a patient with the correct illness is necessary to treat any disease, and recent diagnostic technologies have emerged that can determine sickness or health on a molecular level. However, most molecular diagnostic tools are costly, labor-intensive, and require advanced lab equipment, making them difficult to deploy in low-resource settings. A synthetic-biology-based diagnostic sensor in the Institute’s living cellular devices platform was developed by Wyss core faculty member James Collins, Termeer Professor of Medical Engineering & Science at the Massachusetts Institute of Technology. It can detect molecules of DNA and RNA with extremely high precision and produces an easy-to-read signal. Crucially, this process can be done at room temperature and does not require any scientific instruments, allowing molecular diagnostics to be brought to the front lines of disease outbreaks. The technology was licensed by Sherlock Biosciences in 2019.Robotic Exosuits for Stroke Rehabilitation,Nearly a million Americans suffer strokes annually, and 80 percent of them lose the ability to use one of their legs normally. Even after undergoing physical therapy, many patients never regain a normal walking gait, grow more prone to falls, and become more sedentary. Wearable “exoskeletons” are being developed to provide support during walking and rehabilitation, but these devices are large, hard, and expensive, limiting their use. Working in the Institute’s bioinspired soft robotics platform, Wyss researchers in the lab of Conor Walsh, John L. Loeb Associate Professor of Engineering and Applied Sciences at SEAS, have created a light, soft, fabric-based “exosuit” that applies assistive force to correct patients’ gait during walking and can be worn during normal daily activities. The exosuit was licensed in 2016 by ReWalk Robotics, which is commercializing it for stroke and multiple sclerosis patients. Laying some groundwork for environmental protection New material sticks to dynamically moving tissues even in the presence of blood Today, a decade after Wyss founded the Institute, 375 full-time staff collaborate and work in 100,000 square feet of research space shared between Harvard’s Longwood Medical Campus and Cambridge sites. The community of scientists, biologists, physicists, chemists, engineers, and clinicians includes 18 core faculty, 16 associate faculty, and numerous students, postdocs, and fellows, as well as more than 25 scientists and engineers recruited from industry with extensive experience in product development and team management across multiple disciplines and fields. In addition to their technology commercialization efforts, Wyss Institute faculty and staff have published more than 2,000 scientific articles, with an average of one paper in Scienceor Natureper month since 2009.“From developing singular insights and cutting-edge approaches to creating bioinspired materials and feats of engineering, the Wyss Institute has and will continue to have a powerful impact,” said Harvard University Provost Alan Garber. “Through the many technologies it creates as well as the partnerships it has cultivated, the institute shines a light on the convening power of Harvard and the creative brilliance of its faculty and staff. We are truly grateful for Mr. Wyss’ generosity and for placing his trust in Harvard.”Garber emphasized the Institute’s alliances with all of the University’s Schools, as well as with other leading academic and clinical institutions in the Boston area and around the world. This collaboration and the bridges it has built between academia and industry have been key to the institute’s ability to accelerate the development of novel diagnostics, therapeutics, and other disruptive technologies.“The Wyss Institute exists because of Hansjörg Wyss’ vision that crossing disciplinary boundaries and collaborating across both different scientific fields and different research institutions is crucial for bringing about transformative change,” said Ingber, who is also a professor of bioengineering at Harvard’s School of Engineering and Applied Sciences. “We are honored and humbled by Mr. Wyss’ continued generosity, and we will continue to strive to push the envelope in both technology innovation and translation of these technologies into products that can bring about near-term positive change worldwide.”A native of Switzerland, Wyss is a philanthropist dedicated to helping save the world’s remaining wild places, protecting and empowering society’s most vulnerable, and encouraging breakthroughs in medicine and science. His philanthropy is made possible by his success in starting and growing a medical research and design company, Pennsylvania-based Synthes USA, whose products have helped millions of patients recover from skeletal and soft-tissue trauma and injuries.Today’s gift is being made through the Wyss Foundation, created in 1998 and known for helping to protect some of the world’s most iconic landscapes — from Montana’s Crown of the Continent to the headwaters of the Amazon River in the Andes Mountains — and ensuring they remain open and accessible to all. Altogether, the Wyss Foundation has invested more than $450 million to help local communities, land trusts, and nonprofit partners conserve more than 40 million acres of land in North America, Africa, Europe, Australia, and South America. Last fall, in a New York Times op-ed, Wyss announced he would donate $1 billion over the next decade to help conserve at least 30 percent of the planet in a natural state by 2030. Adhesives that can seal wounds Related
September 23, 2020
The 7/8 Lady Cardinals hosted the Milan Indians. Two great games that gave us both a win for the night.The 7th Grade Lady Cards won with a final score of 34-11. Scoring for SLS were Catherine Streator with 11pts, Claire Saner with 10 pts, Kate Weber bringing 6 pts, Izza Wonnell with 3 pts, and both scoring 2 pts each were Ava Owens and Rhea Miller. We had a really great defensive game by all. They are now 8-0 on the season.The 8th Grade Girls had a great game also. They had a final score of 23-20. Scoring for SLS were Megan Bauer with 9 pts, Summer Ratcliffe with 6 pts, Kate Weber with 5 pts, Sadie Wachsmann with 2 pts, and Anna Wanstrath bringing us 1 pt. Haley Geisen brought us one of her best defensive games to date 5 steals on the night and numerous times got tangled on defense for the jump ball. Our rebounds were being pulled down by Kate Weber and Summer Ratcliffe! Nice job by all!Courtesy of Cardinals Coach Erin Trenkamp.
August 26, 2020
With 10 teams off and only one preseason ace taking the hill, Monday’s SP rankings leave much to be desired. Finding one pitcher for FanDuel contests is doable, but finding two you like on DraftKings could be a challenge, especially with our top two guys pitching in the same game. UPDATE: The Tigers-Red Sox game has been postponed, so ignore the rest of this paragraph. You’ll see it again tomorrow. We had to note “preseason ace” in the last paragraph because Chris Sale (vs. Tigers) has pitched like anything but this year. In fact, his opponent tonight, Detroit’s Matthew Boyd (@ Red Sox), has outpitched him by every metric. Still, we know Sale has the talent to figure it out, and his matchup on paper is just about as good as it gets. We give him the nod over Boyd, but Boyd is priced higher on both DraftKings and FanDuel, making this one of the few times you can qualify Sale as a “bargain”. MORE: Monday DraftKings Lineup Jeremy Hellickson (@ Rockies) is one of the few pitchers with the numbers in his favor, but we know the Rockies are going to start hitting righties better eventually, especially now that they’re back at home. You could make a case he’s a good candidate for a cheap win, but he’ll need to make it through five innings first. In Colorado, that’s never guaranteed.Today’s Starting Pitcher Rankings: Monday, April 22RankPitcherTeamOpponentOpp. wRC+ vs. LHP (rank)Opp. wRC+ vs. RHP (rank)1Chris SaleRed Soxvs. Tigers58 (29th)N/A2Matthew [email protected] Red Sox83 (19th)N/A3J.A. [email protected] Angels71 (23rd)N/A4Jack FlahertyCardinalsvs. BrewersN/A104 (15th)5Yonny ChirinosRaysvs. RoyalsN/A107 (T-11th)6Jake [email protected] MetsN/A101 (17th)7Joe MusgrovePiratesvs. D-backsN/A96 (18th)8Zack [email protected] PiratesN/A86 (21st)9Brad [email protected] RaysN/A117 (T-5th)10Brad PeacockAstrosvs. TwinsN/A122 (T-3rd)11Steven MatzMetsvs. Phillies111 (11th)N/A12David HessOriolesvs. White SoxN/A102 (16th)13Jake [email protected] AstrosN/A117 (T-5th)14Manny BanuelosWhite [email protected] Orioles88 (15th)N/A15Mike [email protected] A’s124 (7th)N/A16Jeremy [email protected] RockiesN/A57 (30th)17Adrian [email protected] CardinalsN/A116 (T-7th)18Chris BassittA’svs. RangersN/A113 (9th)19Matt HarveyAngelsvs. YankeesN/A122 (T-3rd)20Tyler AndersonRockiesvs. Nationals119 (8th)N/AwRC+ is defined by Fangraphs as “[measuring] how a player’s wRC compares with league average after controlling for park effects. League average for position players is 100, and every point above 100 is a percentage point above league average. For example, a 125 wRC+ means a player created 25% more runs than a league average hitter would have in the same number of plate appearances. Similarly, every point below 100 is a percentage point below league average, so a 80 wRC+ means a player created 20% fewer runs than league average.” For more on the stat, click here. Watch ChangeUp, a new MLB live whip-around show on DAZNJack Flaherty (vs. Brewers) was a borderline ace in preseason rankings, and while his K-to-BB ratio is a stellar 22/4, he’s already allowed four HRs. Three of those have come against tonight’s opponent, and while the Brewers are only 15th in wRC+ against righties, Christian Yelich alone is enough to make you consider fading Flaherty. It’s worth noting both of his starts this year against Milwaukee came in Miller Park, and for his short career, he’s been much better at home (3.03 ERA) than on the road (4.52). It’s not easy to identify many more worthwhile DFS sleepers/season-long streamers just by looking at the matchups on paper. It’s tempting to get excited about Zack Godley (@ Pirates), who seems due for a bounce back and is in a pitchers park on the road, but his career road ERA (4.50) is almost identical to his home mark (4.51), so there isn’t much to go on there. Yonny Chirinos (vs. Royals) has been dominant in three of his four outings this year, but he’s also only gone more than five innings once. Steven Matz (vs. Phillies) couldn’t record an out when he faced the Phillies last week, so the Law of Averages is in his favor, if that’s your thing.
August 9, 2019
Campus safety. Universities will be held accountable to better protect students. This plan includes provisions to raise standards for handling sexual assault complaints at universities. Categories: Alexander News,News Jackson County schools receiving top per-student allowance